Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K3 | P46734 | 2/20 | 0.46 |
| ▸ | RORC | P51449 | 9/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 4/20 | 0.36 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333043 | 0.91 | MAP3K14 (0.42) | MAP2K3RORCDGAT2CNR2MAPK14 | |
| SCHEMBL4330621 | 0.89 | RORC (0.42) | MAP2K3RORCDGAT2CNR2PPARG | |
| SCHEMBL4334549 | 0.89 | HIF1A (0.45) | MAP2K3RORCDGAT2CNR2HTR4 | |
| SCHEMBL13578207 | 0.89 | DGAT2 (0.46) | MAP2K3RORCDGAT2CNR2HTR4 | |
| SCHEMBL4325619 | 0.88 | GAA (0.47) | MAP2K3RORCDGAT2CNR2HTR4 | |
| SCHEMBL4333399 | 0.88 | RORC (0.40) | MAP2K3RORCDGAT2CNR2RAD51 | |
| SCHEMBL4327073 | 0.88 | MAP2K3 (0.54) | MAP2K3RORCDGAT2CNR2MAPK14 | |
| SCHEMBL4324747 | 0.87 | OPRD1 (0.41) | MAP2K3RORCDGAT2CNR2HTR4 | |
| SCHEMBL4330451 | 0.86 | HIF1A (0.46) | MAP2K3RORCDGAT2CNR2HTR4 | |
| SCHEMBL4332898 | 0.86 | HIF1A (0.47) | MAP2K3RORCDGAT2CNR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | MAP2K3 1970/4885RORC 135/4885DGAT2 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.